BMS drops HCV drug after death
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb has discontinued development of BMS-986094 (BMS-094, formerly known as INX-189). The nucleotide polymerase (NS5B) inhibitor, which was in Phase II development for the treatment of hepatitis C, was the driver behind BMS' $2.5 billion acquisition of Inhibitex at the start of this year (scripintelligence.com, 9 January 2012).
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: